Drug intelligence / Profile preview

SY-316

Development stage: Preclinical
Lead developer: Seinda Corporation
Administration: Ophthalmic, Topical

Overview

SY-316 is an investigational therapeutic candidate currently in the preclinical stage of development by Seinda Biomedical. It is being developed for ophthalmic immune modulation, targeting immune-mediated or inflammatory conditions of the eye. As of the current pipeline disclosures, the specific molecular target, modality, and mechanism of action remain undisclosed. The drug is intended for topical ophthalmic administration to address unmet needs in ocular immunology.

Targets

BCL9 (B-cell lymphoma 9 protein)

Beyond the preview

Go deeper on SY-316.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SY-316.

Explore the full profile